Wednesday, May 11, 2022 / 3:00 PM - 4:00 PM EDT
Title: Viscoelastography and Platelet Function Tests in Bleeding Patients
Majed Refaai, MD
Professor, Pathology and Lab Medicine
University of Rochester
Dr. Refaai is a Professor of Pathology and Laboratory Medicine at the University of Rochester Medical Center, Rochester, NY. At Strong Memorial Hospital, he serves as the Director of the Thrombosis and Hemostasis Lab and the Associate Director of the Blood Bank/Transfusion Medicine Department and the Clinical Laboratory Department, and he holds an appointment as an Associate Director of the Therapeutic Apheresis Unit in the Internal Medicine/Hematology Department. Dr. Refaai is also the medical director of a few CSL plasma centers in upstate NY. Dr. Refaai received his medical degree from the Aleppo University School of Medicine in Syria. He then joined Massachusetts General Hospital-Harvard Medical School in Boston as a research fellow in a special coagulation research lab. Dr. Refaai completed a residency in clinical pathology at the Washington University School of Medicine in St. Louis, MO, and held a fellowship in transfusion medicine at the University of Texas Southwestern in Dallas, TX. His research focuses on the in vitro and in vivo effects of ABO antibodies and ABO immuno-complexes on platelet function, coagulation processes, and endothelial cell integrity. Dr. Refaai is also working on developing a platelet micro-particles lysate that can be used to control bleeding. This product has been patented. Another patent that Dr. Refaai is developing currently is an ABO point-of-care testing device. He is also involved in pharmaceutical clinical trials of emergency reversal of coagulopathy, as well as treatments for deep vein thrombosis and thrombotic thrombocytopenic purpura. Dr. Refaai is board-certified in clinical pathology and has published more than 130 peer reviewed articles and book chapters.
Trauma is the leading cause of death in individuals under 45 years of age and the fourth leading cause of all ages. The prompt and appropriate management of bleeding in penetrating traumas play a significant role in patient outcomes. Laboratory tests are substantial tools that reflect patient hemostasis status. Thus, the appropriate blood products and hemostatic pharmaceutical agents can be administered promptly and accurately to help facilitate clot formation.
- Review normal hemostasis and clot formation process.
- Understand challenges in clot formation and management in bleeding patients.
- Assess the appropriate bleeding screening tests in trauma.
- Evaluate new approaches and policies in blood management in bleeding patients.
Consulting/Advisory board: CSL Behring, Diagnostica Stago, Cerus, Octapharma, iLine Microsystems
Research Support: CSL Behring, Octapharma, Diagnostica Stago, Werfen, iLine Microsystems
Honoria: CSL Behring, Cerus, Diagnostica Stago
- Members: FREE (Registration is required.)
- Non-Members: $45 per session & $130 entire series
- Institutions: $75 per session & $200 entire series
To receive member pricing, be sure to sign in.